Showing 7101-7110 of 8468 results for "".
- FDA Clears New Underarm Sweat Control Patchhttps://practicaldermatology.com/news/fda-clears-new-underarm-sweat-control-patch/2461660/The U.S. Food and Drug Administration (FDA) has cleared cleared Brella, the first 3-Minute SweatControl Patch to significantly reduce excessive underarm sweating in adults with primary axillary hyperhidrosis. The Brella SweatControl Patch provide
- Eczema Breakthrough: S. aureus Evolve to a Variant with a Mutation in a Specific Gene to Grow Fasterhttps://practicaldermatology.com/news/eczema-breakthrough-s-aureus-evolve-to-a-variant-with-a-mutation-in-a-specific-gene-to-grow-faster/2461659/New research shows how Staphylococcus aureus gains mutations that allow it to colonize eczema patches. In people with eczema, S. aureus tends to evolve to a variant with a mutation in a specific gene that helps it grow faster on the skin. This study marks the first t
- Prior Immunotherapy May Predict Response to PD-1 Checkpoint Blockadehttps://practicaldermatology.com/news/prior-immunotherapy-may-predict-response-to-pd-1-checkpoint-blockade/2461655/Responses to PD-1 checkpoint blockade in patients with advanced melanoma depend on whether or not they had previously received CTLA-4 blockade as well as other factors, new research suggests. Their findings, based on analysis of seven data sets generated over the past decade, which incl
- Cutera CEO, Executive Chairman Axedhttps://practicaldermatology.com/news/shake-up-at-cutera-shareholder-ceo-look-to-reconstitute-board/2461654/Cutera, Inc. has fired CEO David Mowry and Executive Chairman Daniel Plants for alleged violations of their employment contracts. Sheila Hopkins has been appointed as interim CEO and the search for a permanent replacement is underway. Plants and Mowry called for a Sp
- Dr. Susan C. Taylor Elected 2025 AAD Presidenthttps://practicaldermatology.com/news/dr-susan-c-taylor-elected-2025-aad-president/2461653/Susan C. Taylor, MD, FAAD is the American Academy of Dermatology’s president-elect. She will be installed in March 2024 and hold the office of president for one year beginning in March 2025. Dr. Taylor previously served as AAD Vice President from 2020 – 2021.
- News You Can Use: BI Receives Permanent J-Code (J1747) for SPEVIGO Injectionhttps://practicaldermatology.com/news/news-you-can-use-bi-receives-permanent-j-code-j1747-for-spevigo-injection/2461649/The U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-code (J1747) for Boehringer Ingelheim’s SPEVIGO (spesolimab-sbzo) Injection, indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults. The J-code for SPEVIGO became eff
- Mount Sinai Wins $1.3M Grant to Expand Skin Biology Research Training Programhttps://practicaldermatology.com/news/mount-sinai-wins-13m-grant-to-expand-skin-biology-research-training-program/2461643/The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai will expand its research training program in skin biology with support from a five-year, $1.3 million T32 grant from the National Institutes of Health (NIH) and the National Institute of Arth
- It's Official: April Is the Coolest Month of the Yearhttps://practicaldermatology.com/news/its-official-april-is-the-coolest-month-of-the-year/2461642/April 2023 marks the first-ever CoolMonth, according to Allergan Aesthetics, an AbbVie company and the parent company of CoolSculpting Elite. Why April? A survey revealed 85% of people have a season in which they begin to think more about getting rid of stubborn body fat
- Researchers Discover Anti-Aging Potential in an Invasive Weedhttps://practicaldermatology.com/news/researchers-discover-anti-aging-potential-in-an-invasive-weed/2461638/The fruit of the cocklebur plant, which grows worldwide and is often considered a noxious weed, has antioxidant and anti-inflammatory components that could make it useful as a skin protectant, according to new research
- Bristol Myers Squibb Receives European Commission Approval of Sotyktu for Plaque Psoriasishttps://practicaldermatology.com/news/bristol-myers-squibb-receives-european-commission-approval-of-sotyktu-for-plaque-psoriasis/2461634/The European Commission has approved Sotyktu (deucravacitinib; Bristol Myers Squibb), a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. The approval was